Xue Zhi Zhao,Steven Smith,Mathieu Metifiot,Barry Johnson,Christophe Marchand,Stephen H. Hughes,Yves Pommier,Terrence R. Burke, Jr.
申请号：
US14891309
公开号：
US09676771B2
申请日:
2014.05.13
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein X is N, C(OH), or CHY is H or OHeach of Z1-Z5 is independently H or halogenR4 is H, OH, NH2, NHR8, NR8R9 or R8R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle andR8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen to which R8 and R9 are attached form an optionally-substituted heterocycle.
